Physician profile
Sanam Loghavi
NPI 1871802199
$94,147.70
in general payments reported to CMS, 2019-2025
17 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $155 · 2022: $11K · 2023: $12K · 2024: $45K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $63K · Travel and Lodging: $16K · Food and Beverage: $3,946 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $229 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $63,245.00 |
| Travel and Lodging | $15,503.60 |
| Food and Beverage | $3,946.14 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $228.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $25,727.85 | 2022-2025 | Vanflyta |
| Servier Pharmaceuticals LLC | $19,568.93 | 2021-2024 | |
| Abbvie INC. | $14,156.46 | 2022-2025 | |
| Celgene Corporation | $10,117.52 | 2023-2024 | |
| Stemline Therapeutics INC. | $7,039.08 | 2019-2025 | Elzonris |
| Syndax Pharmaceuticals, INC. | $6,800.00 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $4,309.21 | 2024 | |
| Blueprint Medicines Corporation | $2,522.50 | 2022 | |
| Tempus Ai, INC | $1,500.00 | 2024 | |
| Genentech USA, INC. | $1,016.86 | 2023-2025 | Venclexta, Polivy, Columvi |
| Astellas Pharma US INC | $606.44 | 2023-2024 | Xospata |
| Astrazeneca Pharmaceuticals Lp | $322.70 | 2023 | |
| Cti Biopharma Corp. | $134.15 | 2023 | Vonjo |
| Taiho Oncology, INC. | $129.08 | 2023 | |
| Janssen Global Services, LLC | $124.25 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.53 | 2019 | |
| Seagen INC. | $33.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanam Loghavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.